BOD1L1

Across TCGA pan-cancer cohorts, BOD1L1 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated BOD1L1 data layer compared with 27 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher BOD1L1 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated BOD1L1 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and PDAC show a favorable association.

HNSC, CCRCC, and PDAC are the cancer types where BOD1L1 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Tertile	All	0.689	0.881	.004	36	view →
CCRCC	DFS	Tertile	III,IV	0.839	0.414	.007	17	view →
PDAC	DFS	Tertile	IV	0.934	0.231	.024	12	view →
GBM	OS	Tertile	All	0.511	0.239	.006	11	view →
LUAD	OS	Tertile	III,IV	0.724	0.176	.020	10	view →
COAD	DFS	Median	II,III,IV	1.000	0.896	.047	6	view →
LSCC	DFS	Tertile	III,IV	0.838	1.000	.036	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

BOD1L1–HNSC (DFS)

Open the HNSC breakdown →